Zimbabwe has rejected a major American health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' demand for confidential information.
This rejection was revealed following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman later stated that the United States was requesting health data for scientific study and commercial gain but was not willing to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued talks to reach a deal suitable to all parties so the nation's vital HIV programme can be sustained.
Wider Implications
This rejection follows a comparable situation in neighbouring Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
According to reports, 16 African countries have so far signed these new health pacts, constituting more than $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for medical research without any certainty that the end products would be accessible to our population if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral health agreements were upending structures already established through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome further dialogue with our American counterparts on how future collaboration might be arranged in a manner that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that negotiations need to persist since much of the nation's Aids initiatives depended on foreign aid.
"Where specific concerns arise, including those relating to information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it added.
This impasse highlights the continuing debate between receiving much-needed foreign assistance and protecting local interests in an ever more data-driven world.